Good Day BIO Newsletter

BIO explains why CMS overreach will impede innovation, and we look at how data can improve clinical trial diversity. (532 words, 2 minutes, 39 seconds)

The FDA approved Merck’s vaccine against pneumococcus bacteria, and a former White House official explains why current Medicare policy will harm access to Alzheimer’s treatments. We’re off tomorrow for Juneteenth—which is also World Sickle Cell Day. We explore biotech’s role in reducing inequities that remain. (648 words, 3 minutes, 14 seconds)We're off Wednesday, June 19, for Juneteenth. We'll return to the regular publishing schedule on Thursday, June 20. 

Starting a new week with a look back at what patient advocates said at BIO 2024, and why patient stories matter—plus, rising temperatures nationwide are a reminder of the need to advance biotech solutions. (640 words, 3 minutes, 12 seconds)

We catch up on a few things from D.C. this week: the creation of the Congressional Sustainable Aviation Caucus, Members of Congress calling for value-based payment models, and more praise for an FDA advisory panel’s donanemab recommendation. (635 words, 3 minutes, 10 seconds)

A new report details the economic impact of America’s industrial bioeconomy, while a few recent studies define and quantify the impacts of long COVID. We have details, plus more on reducing the industry’s emissions from BIO 2024. (707 words, 3 minutes, 32 seconds)

New gene therapies will be here soon—but payment models are stuck in the 20th century, said experts at the BIO International Convention. Plus, the onus is on innovators to educate regulators about their science—a few companies explain why. (584 words, 2 minutes, 55 seconds)

An FDA advisory panel recommends approval of Eli Lilly’s Alzheimer's drug donanemab, parents explain why we need to reauthorize the Rare Pediatric Disease Priority Review Voucher Program (PPRV), and we recap BIO 2024 sessions on women’s health. (611 words, 3 minutes, 3 seconds)

GSK’s RSV vaccine was approved for an expanded population, and a new study confirms an option for infants is effective. Plus, our BIO 2024 coverage is not over yet—and today, we get the patient perspective on PDABs and the IRA. (558 words, 2 minutes, 47 seconds)

We’re wrapping up a fantastic 2024 BIO International Convention with what FDA Commissioner Dr. Robert Califf said about supply chains (and more) and how you can get involved with ARPA-H—plus, a few headlines you might have missed. (703 words, 3 minutes, 30 seconds)

On Day 3 of the BIO International Convention, we learned about the National Security Commission on Emerging Biotechnology—more on that, plus a few takeaways on leadership and innovation. (729 words, 3 minutes, 38 seconds)